glp-1 news today receptor agonists show promise in treating substance use disorders GLP-1 Drugs May Expand Beyond
Description
This is a relatively nascent market driven by clinical efficacy that is truly unprecedented
It is estimated that nearly 60% of depressive episodes are preceded by an exposure to various types of stressors [69]
Important safety considerations include the risk of pancreatitis (all GLP-1 agonists carry warnings about this), gallbladder disease (more common with greater weight loss), and a caution with semaglutide in patients with pre-existing diabetic retinopathy, where rapid improvement in glucose control may temporarily worsen retinopathy
BPC-157 BPC-157 vials typically come in 5 mg
